Kathrin Reetz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7051888/publications.pdf

Version: 2024-02-01

66315 85498 6,532 164 42 71 citations h-index g-index papers 178 178 178 9370 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder – a clue to early peripheral autonomic and sensory dysfunction?. Journal of Neurology, 2022, 269, 923-932.	1.8	5
2	Cognitive Decline Is Closely Associated with Ataxia Severity in Spinocerebellar Ataxia Type 2: a Validation Study of the Schmahmann Syndrome Scale. Cerebellum, 2022, 21, 391-403.	1.4	20
3	Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2022, 109, 31-42.	1.5	12
4	Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity. Movement Disorders, 2022, 37, 405-410.	2.2	8
5	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 905-916.	1.5	7
6	Long COVIDâ€19: Objectifying most selfâ€reported neurological symptoms. Annals of Clinical and Translational Neurology, 2022, 9, 141-154.	1.7	67
7	Nach 1ÂJahr Deutsche Hirnstiftung: erste Meilensteine erreicht. DGNeurologie, 2022, 5, 95-96.	0.0	O
8	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. Journal of Alzheimer's Disease, 2022, 87, 185-195.	1.2	6
9	The CCAS-scale in hereditary ataxias: helpful on the group level, particularly in SCA3, but limited in individual patients. Journal of Neurology, 2022, 269, 4363-4374.	1.8	13
10	Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. Neurology, 2022, 98, .	1.5	15
11	Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study. Neurolmage: Clinical, 2022, 34, 103025.	1.4	3
12	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	1.7	25
13	The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103837.	0.9	4
14	Association between probable REM sleep behavior disorder and increased dermal alpha-synuclein deposition in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 99, 58-61.	1.1	9
15	Differential Temporal Dynamics of Axial and Appendicular Ataxia in <scp>SCA3</scp> . Movement Disorders, 2022, 37, 1850-1860.	2.2	11
16	Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson's disease on behalf of the German rapid eye movement sleep behavior disorder study group. Sleep, 2021, 44, .	0.6	26
17	Fourâ€Year <scp>Followâ€up</scp> of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography–Based Parkinson's Disease–Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression. Movement Disorders, 2021, 36, 230-235.	2.2	31
18	Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment. Brain Communications, 2021, 3, fcab191.	1.5	23

#	Article	IF	Citations
19	Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2021, 79, 1661-1672.	1.2	8
20	Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurological Research and Practice, 2021, 3, 17.	1.0	44
21	Functional MRI Derived Resting-State Alterations in Huntington's Disease are Associated With the Distribution of Serotonergic and Dopaminergic Neurotransmitter Systems. Biological Psychiatry, 2021, 89, S172.	0.7	2
22	Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3. Movement Disorders, 2021, 36, 2273-2281.	2.2	37
23	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurology, The, 2021, 20, 362-372.	4.9	53
24	Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease. European Journal of Neurology, 2021, 28, 2855-2862.	1.7	8
25	Functional parcellation of human and macaque striatum reveals human-specific connectivity in the dorsal caudate. Neurolmage, 2021, 235, 118006.	2.1	29
26	LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort. Frontiers in Neurology, 2021, 12, 710572.	1.1	3
27	Polyglutamineâ€Expanded Ataxinâ€3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood. Movement Disorders, 2021, 36, 2675-2681.	2.2	22
28	Incident stroke in patients with Alzheimer's disease: systematic review and meta-analysis. Scientific Reports, 2021, 11, 16385.	1.6	11
29	A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. Parkinsonism and Related Disorders, 2021, 90, 90-97.	1.1	5
30	Brain Structure and Degeneration Staging in Friedreich Ataxia: <scp>Magnetic Resonance Imaging < /scp> Volumetrics from the <scp>ENIGMAâ€Ataxia < /scp> Working Group. Annals of Neurology, 2021, 90, 570-583.</scp></scp>	2.8	27
31	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	1.2	4
32	Reference values for the Cerebellar Cognitive Affective Syndrome Scale: age and education matter. Brain, 2021, 144, e20-e20.	3.7	14
33	Novel CACNA1A Variant p.Cys256Phe Disrupts Disulfide Bonds and Causes Spinocerebellar Ataxia. Movement Disorders, 2021, , .	2.2	3
34	Increased neural motor activation and functional reorganization in patients with idiopathic rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2021, 92, 76-82.	1.1	6
35	What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. Alzheimer's and Dementia, 2021, 17, 1843-1854.	0.4	6
36	Everyday Life Tremor Signal Processing in PD Patients using BSN., 2021,,.		0

#	Article	IF	CITATIONS
37	The prevalence of vascular risk factors in different AD biomarker profiles. Alzheimer's and Dementia, 2021, 17, .	0.4	О
38	Incident stroke in patients with Alzheimer's disease: A metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
39	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48.	0.9	16
40	Changes in brain activation related to visuo-spatial memory after real-time fMRI neurofeedback training in healthy elderly and Alzheimer's disease. Behavioural Brain Research, 2020, 381, 112435.	1,2	8
41	Neurochemical profiles in hereditary ataxias: A meta-analysis of Magnetic Resonance Spectroscopy studies. Neuroscience and Biobehavioral Reviews, 2020, 108, 854-865.	2.9	18
42	MR imaging and spectroscopy in degenerative ataxias: toward multimodal, multisite, multistage monitoring of neurodegeneration. Current Opinion in Neurology, 2020, 33, 451-461.	1.8	13
43	Disease modifying treatment trials in Parkinson's disease: how to balance expectations and interests of patients, physicians and industry partners?. Neurological Research and Practice, 2020, 2, 31.	1.0	2
44	Joint Multi-modal Parcellation of the Human Striatum: Functions and Clinical Relevance. Neuroscience Bulletin, 2020, 36, 1123-1136.	1.5	14
45	Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurology, The, 2020, 19, 738-747.	4.9	41
46	Validation of a German version of the Cerebellar Cognitive Affective/ Schmahmann Syndrome Scale: preliminary version and study protocol. Neurological Research and Practice, 2020, 2, 39.	1.0	13
47	Quantitative sodium imaging using ultraâ€high field magnetic resonance imaging in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042107.	0.4	1
48	Investigating Neurocognitive Functioning in Youths With Externalizing Disorders From the Philadelphia Neurodevelopmental Cohort. Journal of Adolescent Health, 2020, 69, 100-107.	1.2	1
49	Effect of a multicomponent exercise intervention on brain metabolism: A randomized controlled trial on Alzheimer's pathology (Dementiaâ€MOVE). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12032.	1.8	12
50	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Molecular Medicine, 2020, 12, e11803.	3.3	73
51	Functional Characterization of Atrophy Patterns Related to Cognitive Impairment. Frontiers in Neurology, 2020, 11, 18.	1.1	12
52	Semiâ€automated volumetry of MRI serves as a biomarker in neuromuscular patients. Muscle and Nerve, 2020, 61, 600-607.	1.0	8
53	Structural characteristics of the central nervous system in FriedreichÂataxia: an in vivo spinal cord and brain MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 615-617.	0.9	33
54	Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI studies. NeuroImage: Clinical, 2019, 23, 101933.	1.4	68

#	Article	IF	CITATIONS
55	Engineered antibodies: new possibilities for brain PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2848-2858.	3.3	49
56	Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurological Research and Practice, 2019, 1, 33.	1.0	14
57	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. Cerebellum, 2019, 18, 896-909.	1.4	9
58	Going beyond the mean: Intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders. Clinical Neuropsychologist, 2019, 33, 369-389.	1.5	43
59	Tissue sodium concentration and sodium T1 mapping of the human brain at 3â€T using a Variable Flip Angle method. Magnetic Resonance Imaging, 2019, 58, 116-124.	1.0	15
60	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Translational Neurodegeneration, 2019, 8, 11.	3.6	10
61	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 229-239.	1.5	12
62	Proton Magnetic Resonance Spectroscopy of the motor cortex reveals long term GABA change following anodal Transcranial Direct Current Stimulation. Scientific Reports, 2019, 9, 2807.	1.6	25
63	Bilingualism in Primary Progressive Aphasia. Alzheimer Disease and Associated Disorders, 2019, 33, 47-53.	0.6	11
64	Functional Connectivity Changes of Key Regions for Motor Initiation in Parkinson's Disease. Cerebral Cortex, 2019, 29, 383-396.	1.6	17
65	Clinical and genetic characteristics of late-onset Huntington's disease. Parkinsonism and Related Disorders, 2019, 61, 101-105.	1.1	17
66	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 171-179.	0.9	54
67	Brain Imaging in RBD. , 2019, , 403-445.		3
68	Sodium Image Denoising Based on a Convolutional Denoising Autoencoder. Informatik Aktuell, 2019, , 98-103.	0.4	2
69	Die teilautomatisierte Volumetrie der Muskel-Magnetresonanztomografie als potenzieller Biomarker bei neuromuskulĤen Patienten. Nervenheilkunde, 2019, 38, .	0.0	O
70	Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. Annals of Clinical and Translational Neurology, 2018, 5, 128-137.	1.7	45
71	The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease. Journal of Nuclear Medicine, 2018, 59, 1437-1444.	2.8	80
72	Impact of gender and genetics on emotion processing in Parkinson's disease - A multimodal study. Neurolmage: Clinical, 2018, 18, 305-314.	1.4	32

#	Article	IF	CITATIONS
73	Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 559-565.	0.9	16
74	Resting-state connectivity in neurodegenerative disorders: Is there potential for an imaging biomarker?. NeuroImage: Clinical, 2018, 18, 849-870.	1.4	186
75	Quality of life in a German cohort of Parkinson's patients assessed with three different measures. Journal of Neurology, 2018, 265, 2713-2722.	1.8	14
76	Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD. Journal of Neurology, 2018, 265, 2548-2561.	1.8	37
77	Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). American Journal of Geriatric Psychiatry, 2018, 26, 1079-1090.	0.6	5
78	Nonataxia symptoms in Friedreich Ataxia. Neurology, 2018, 91, e917-e930.	1.5	46
79	Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. Journal of Huntington's Disease, 2018, 7, 209-222.	0.9	14
80	H32â€Neuronal correlates and clinical predictors for dysphagia in huntington's disease. , 2018, , .		0
81	Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – A systematic review on potential biomarkers for neurodegeneration. Sleep Medicine Reviews, 2017, 34, 23-33.	3.8	76
82	Blood RNA biomarkers in prodromal PARK4 and REM sleep behavior disorder show role of complexin-1 loss for risk of Parkinson's disease. DMM Disease Models and Mechanisms, 2017, 10, 619-631.	1.2	20
83	Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease. International Journal of Methods in Psychiatric Research, 2017, 26, .	1.1	10
84	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
85	On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivityâ€based singleâ€subject classification. Human Brain Mapping, 2017, 38, 5845-5858.	1.9	35
86	FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. Movement Disorders, 2017, 32, 1482-1486.	2.2	67
87	Cognitive decline in Huntington's disease expansion gene carriers. Cortex, 2017, 95, 51-62.	1.1	50
88	Cognitive Improvement and Brain Changes after Real-Time Functional MRI Neurofeedback Training in Healthy Elderly and Prodromal Alzheimer's Disease. Frontiers in Neurology, 2017, 8, 384.	1.1	41
89	Impaired Emotional Mirroring in Parkinson's Disease—A Study on Brain Activation during Processing of Facial Expressions. Frontiers in Neurology, 2017, 8, 682.	1.1	20
90	Differential Functional Connectivity Alterations of Two Subdivisions within the Right dlPFC in Parkinson's Disease. Frontiers in Human Neuroscience, 2017, 11, 288.	1.0	18

#	Article	IF	CITATIONS
91	Posterior Cortical Atrophy. Alzheimer Disease and Associated Disorders, 2016, 30, 276-280.	0.6	2
92	Functional Connectivity Differences of the Subthalamic Nucleus Related to <scp>P</scp> arkinson's Disease. Human Brain Mapping, 2016, 37, 1235-1253.	1.9	25
93	Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. Psychological Medicine, 2016, 46, 2275-2286.	2.7	14
94	Apolipoprotein E $\hat{l}\mu 4$ does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	1.1	22
95	Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology, 2016, 87, 571-578.	1.5	37
96	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurology, The, 2016, 15, 1346-1354.	4.9	117
97	D26â€Pathological tau signal in huntington's disease – an in vivo [18F]-AV-1451 pet imaging report. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A44.1-A44.	0.9	2
98	D14â€Resting-state connectivity changes in huntington's disease: a follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A38.3-A39.	0.9	0
99	Cognition in Friedreich's ataxia: a behavioral and multimodal imaging study. Annals of Clinical and Translational Neurology, 2016, 3, 572-587.	1.7	50
100	Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder. Parkinsonism and Related Disorders, 2016, 29, 10-16.	1.1	29
101	Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. PLoS ONE, 2016, 11, e0164953.	1.1	21
102	Increased Cerebral Water Content in Hemodialysis Patients. PLoS ONE, 2015, 10, e0122188.	1.1	22
103	Clinical diagnosis and management in early Huntington's disease: a review. Degenerative Neurological and Neuromuscular Disease, 2015, 5, 37.	0.7	6
104	The intrinsic resting state voice network in Parkinson's disease. Human Brain Mapping, 2015, 36, 1951-1962.	1.9	38
105	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurology, The, 2015, 14, 174-182.	4.9	159
106	Blunted Brain Energy Consumption Relates to Insula Atrophy and Impaired Glucose Tolerance in Obesity. Diabetes, 2015, 64, 2082-2091.	0.3	32
107	Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease. Neurolmage: Clinical, 2015, 7, 640-652.	1.4	27
108	Effect of MAOA Genotype on Resting-State Networks in Healthy Participants. Cerebral Cortex, 2015, 25, 1771-1781.	1.6	25

#	Article	IF	CITATIONS
109	Consensus Paper: Radiological Biomarkers of Cerebellar Diseases. Cerebellum, 2015, 14, 175-196.	1.4	42
110	Specific and disease stage-dependent episodic memory-related brain activation patterns in Alzheimer's disease: a coordinate-based meta-analysis. Brain Structure and Function, 2015, 220, 1555-1571.	1.2	46
111	The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. PLoS ONE, 2014, 9, e106700.	1.1	130
112	Neural correlates of impaired emotion processing in manifest Huntington's disease. Social Cognitive and Affective Neuroscience, 2014, 9, 671-680.	1. 5	44
113	Evidence of the Sensitivity of the MoCA Alternate Forms in Monitoring Cognitive Change in Early Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 37, 95-103.	0.7	43
114	Altered restingâ€state connectivity in Huntington's Disease. Human Brain Mapping, 2014, 35, 2582-2593.	1.9	82
115	The processing of lexical ambiguity in healthy ageing and Parkinson×3s disease: Role of cortico-subcortical networks. Brain Research, 2014, 1581, 51-63.	1.1	12
116	Clinical Predictors of Individual Cognitive Fluctuations in Patients Undergoing Hemodialysis. American Journal of Kidney Diseases, 2014, 64, 434-442.	2.1	50
117	Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?., 2014, 5, 63-75.		33
118	Cognitive effects of deep brain stimulation for essential tremor: evaluation at 1 and $6\hat{A}$ years. Journal of Neural Transmission, 2013, 120, 1569-1577.	1.4	23
119	Differentiated parietal connectivity of frontal regions for "what―and "where―memory. Brain Structure and Function, 2013, 218, 1551-1567.	1.2	86
120	Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurology, The, 2013, 12, 650-658.	4.9	167
121	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74
122	Consistent Neurodegeneration and Its Association with Clinical Progression in Huntington's Disease: A Coordinate-Based Meta-Analysis. Neurodegenerative Diseases, 2013, 12, 23-35.	0.8	64
123	Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain, 2013, 136, 905-917.	3.7	128
124	\hat{l}^2 -Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 107-124.	0.9	1
125	Upcoming Meetings Related to Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 135-135.	0.9	0
126	Multisensory integration mechanisms during aging. Frontiers in Human Neuroscience, 2013, 7, 863.	1.0	134

#	Article	IF	CITATIONS
127	Diminished Activation of Motor Working-Memory Networks in Parkinson's Disease. PLoS ONE, 2013, 8, e61786.	1.1	29
128	Parkinson-Syndrom, Chorea Huntington., 2013,, 549-561.		0
129	Alternate-Form Reliability of the Montreal Cognitive Assessment Screening Test in a Clinical Setting. Dementia and Geriatric Cognitive Disorders, 2012, 33, 379-384.	0.7	93
130	Modelling neural correlates of working memory: A coordinate-based meta-analysis. NeuroImage, 2012, 60, 830-846.	2.1	777
131	Investigating function and connectivity of morphometric findings — Exemplified on cerebellar atrophy in spinocerebellar ataxia 17 (SCA17). NeuroImage, 2012, 62, 1354-1366.	2.1	72
132	Increased brain tissue sodium concentration in Huntington's Disease â€" A sodium imaging study at 4T. Neurolmage, 2012, 63, 517-524.	2.1	67
133	Skill Memory Escaping from Distraction by Sleepâ€"Evidence from Dual-Task Performance. PLoS ONE, 2012, 7, e50983.	1.1	11
134	Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. Brain Structure and Function, 2012, 217, 115-125.	1.2	67
135	Bildgebung genetischer Aspekte des Parkinson-Syndroms. , 2012, , 153-157.		0
136	CAG Repeats Determine Brain Atrophy in Spinocerebellar Ataxia 17: A VBM Study. PLoS ONE, 2011, 6, e15125.	1.1	19
137	Structural Abnormalities in Parkinson's Disease. , 2011, , 32-50.		0
138	Structural Changes Associated with Progression of Motor Deficits in Spinocerebellar Ataxia 17. Cerebellum, 2010, 9, 210-217.	1.4	33
139	Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning. Neurobiology of Disease, 2010, 37, 455-460.	2.1	46
140	Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiology of Disease, 2010, 39, 402-408.	2.1	43
141	Recessively Inherited Parkinsonism. Archives of Neurology, 2010, 67, 1357-63.	4.9	73
142	Digitized spiral analysis is a promising early motor marker for Parkinson Disease. Parkinsonism and Related Disorders, 2010, 16, 233-234.	1.1	36
143	Heterozygous carriers of a <i>Parkin</i> or <i>PINK1</i> mutation share a common functional endophenotype. Neurology, 2009, 72, 1041-1047.	1.5	66
144	Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Movement Disorders, 2009, 24, 99-103.	2.2	50

#	Article	IF	Citations
145	<i>ATP13A2</i> variants in earlyâ€onset Parkinson's disease patients and controls. Movement Disorders, 2009, 24, 2104-2111.	2.2	62
146	Limbic and Frontal Cortical Degeneration Is Associated with Psychiatric Symptoms in PINK1 Mutation Carriers. Biological Psychiatry, 2008, 64, 241-247.	0.7	43
147	Apraxia., 2008,, 67-88.		2
148	Premotor Gray Matter Volume is Associated with Clinical Findings in Idiopathic and Genetically Determined Parkinson's Disease. Open Neuroimaging Journal, 2008, 2, 102-105.	0.2	5
149	Enhanced heterogeneity of myocardial conduction and severe cardiac electrical instability in annexin A7-deficient mice. Cardiovascular Research, 2007, 76, 257-268.	1.8	47
150	PREDOMINANT DYSTONIA WITH MARKED CEREBELLAR ATROPHY: A RARE PHENOTYPE IN FAMILIAL DYSTONIA. Neurology, 2007, 68, 2157-2158.	1.5	13
151	Tactile agnosia and tactile apraxia: Cross talk between the action and perception streams in the anterior intraparietal area. Behavioral and Brain Sciences, 2007, 30, 201-202.	0.4	46
152	Morphometric fingerprint of asymptomatic <i>Parkin</i> and <i>PINK1</i> mutation carriers in the basal ganglia. Neurology, 2007, 69, 842-850.	1.5	66
153	Phenotypic spectrum of PINK1-associated parkinsonism in 15 mutation carriers from 1 family. Movement Disorders, 2007, 22, 145-147.	2.2	19
154	Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17). Brain, 2006, 129, 2341-2352.	3.7	102
155	Clinical Spectrum of Homozygous and Heterozygous PINK1 Mutations in a Large German Family With Parkinson Disease. Archives of Neurology, 2006, 63, 833.	4.9	151
156	Functional MRI for immediate monitoring stereotactic thalamotomy in a patient with essential tremor. European Radiology, 2006, 16, 2229-2233.	2.3	15
157	No double-dissociation between optic ataxia and visual agnosia: Multiple sub-streams for multiple visuo-manual integrations. Neuropsychologia, 2006, 44, 2734-2748.	0.7	244
158	Intraoperative functional MRI as a new approach to monitor deep brain stimulation in Parkinson's disease. European Radiology, 2004, 14, 686-690.	2.3	39
159	Functional MRI using multiple receiver coils: BOLD signal changes and signal-to-noise ratio for three-dimensional-PRESTO vs. single shot EPI in comparison to a standard quadrature head coil. Journal of Magnetic Resonance Imaging, 2004, 20, 321-326.	1.9	9
160	Discriminating the Cortical Representation Sites of Tongue and Lip Movement by Functional MRI. Brain Topography, 2003, 16, 159-167.	0.8	42
161	Force/shortening–frequency relationship in multicellular muscle strips and single cardiomyocytes of human failing and nonfailing hearts. Journal of Cardiac Failure, 2001, 7, 335-341.	0.7	19
162	Loss of Annexin A7 Leads to Alterations in Frequency-Induced Shortening of Isolated Murine Cardiomyocytes. Molecular and Cellular Biology, 2001, 21, 4119-4128.	1.1	78

#	Article	IF	CITATIONS
163	Ataxia., 0,, 204-228.		O
164	Verdachtsdiagnose: Demenz – Was ist nun zu tun?. , 0, , .		0